[go: up one dir, main page]

AR050693A1 - Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. - Google Patents

Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Info

Publication number
AR050693A1
AR050693A1 ARP050103369A ARP050103369A AR050693A1 AR 050693 A1 AR050693 A1 AR 050693A1 AR P050103369 A ARP050103369 A AR P050103369A AR P050103369 A ARP050103369 A AR P050103369A AR 050693 A1 AR050693 A1 AR 050693A1
Authority
AR
Argentina
Prior art keywords
immune response
suppression
interleuquina
mutant
compositions containing
Prior art date
Application number
ARP050103369A
Other languages
English (en)
Original Assignee
Zheng Xin Xiao
Thomas Moll
Strom Terry B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zheng Xin Xiao, Thomas Moll, Strom Terry B filed Critical Zheng Xin Xiao
Publication of AR050693A1 publication Critical patent/AR050693A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Métodos de tratamiento de pacientes que han recibido, o programados para recibir, un transplante de corazon, de pulmon o cardio-pulmonar mediante la administracion a dichos pacientes de un agente que antagoniza la IL-15 o al receptor de IL-15 (IL- 15R). Reivindicacion 13: Uso de un polipéptido o de una molécula de ácido nucleico, caracterizado porque es para suprimir supresion de una respuesta inmune dependiente de IL-15, donde el polipéptido comprende la SEQ ID No.:6 y la molécula de ácido nucleico comprende una secuencia que codifica al polipéptido de la SEQ ID No.:6.
ARP050103369A 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. AR050693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60104204P 2004-08-11 2004-08-11
US60047804P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
AR050693A1 true AR050693A1 (es) 2006-11-15

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante

Country Status (4)

Country Link
US (2) US20060057680A1 (es)
AR (2) AR050293A1 (es)
TW (2) TW200613552A (es)
WO (2) WO2006020849A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2007084342A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
JP2017536098A (ja) * 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
WO2017046200A1 (en) * 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
BR112018012262A2 (pt) * 2015-12-21 2018-12-04 Armo Biosciences Inc composições de interleucina-15 e seus usos
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
KR102706743B1 (ko) * 2016-12-21 2024-09-19 세파론 엘엘씨 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CA3091857A1 (en) * 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
CA3131533A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CA3136241A1 (en) 2019-05-20 2020-11-26 Ulrich Moebius Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
IL302321B2 (en) 2020-10-26 2025-09-01 Cytune Pharma IL-2/IL-15RβY agonist for the treatment of squamous cell carcinoma
US20230398185A1 (en) 2020-10-26 2023-12-14 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
ATE298367T1 (de) * 1996-04-26 2005-07-15 Beth Israel Hospital Interleukin-15 antagoniste
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15

Also Published As

Publication number Publication date
WO2006020849A2 (en) 2006-02-23
WO2006017853A2 (en) 2006-02-16
US20060057680A1 (en) 2006-03-16
TW200619227A (en) 2006-06-16
WO2006017853A3 (en) 2007-01-04
TW200613552A (en) 2006-05-01
AR050293A1 (es) 2006-10-11
US20060057102A1 (en) 2006-03-16
WO2006020849A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR050693A1 (es) Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
SG131109A1 (en) Muteins of tear lipocalin
SI2351579T1 (sl) Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
EA200501363A1 (ru) Состав для ингалятора, выдающего мерную дозу препарата, с использованием гидрофторалканов в качестве пропеллентов
CA2638826C (en) A mycobacterium tuberculosis fusion protein and uses thereof
UA27788C2 (uk) Композиція, що містить виділений фактор лелістада, вакцинна композиція для вакцинації тварин (варіанти), діагностичний набір для виявлення антитіла
GB9818627D0 (en) Improvements in dva vaccination
ATE410178T1 (de) Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
BR0214496A (pt) Métodos e composições a base de peroxigênio para limpeza ou sanitização de tapete ou estofamento
PL1673068T3 (pl) Kompozycja farmaceutyczna sprzyjająca transportowi tlenu do skóry
JP2008523805A5 (es)
Mair Mummies of the Tarim basin.
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
MX2009012676A (es) Neuraminidasa neumococica no toxica y sus usos.
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
NZ593200A (en) Peptide adjuvants
MXPA05011595A (es) Composiciones de spex y metodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure